Intermittent Fasting and GLP-1 Medications: Timing, Safety, and What the Evidence Says

What do the trials and labels say about fasting?

The Wegovy and Zepbound labels describe treatment in combination with a reduced-calorie diet and increased physical activity [1][3]. In STEP 1, semaglutide 2.4 mg was compared with placebo, each added to lifestyle intervention, in 1,961 adults without diabetes [5]. SURMOUNT-1 compared tirzepatide with placebo plus lifestyle in 2,539 adults without diabetes [6]. Neither trial tested a fasting window.

What do the labels say about timing?

Wegovy, Ozempic and Zepbound are given once weekly at any time of day, with or without meals [1][2][3]. Oral semaglutide is different. The Wegovy tablet label says to take it once daily on an empty stomach in the morning with water (up to 4 ounces), not other liquids, and to wait at least 30 minutes before eating food, drinking beverages or taking other oral medications [1]. The Rybelsus and Ozempic tablet label has the same empty-stomach, 4-ounce water and 30-minute rules [4].

What safety issues matter if fasting makes you eat less?

Gastrointestinal effects are common, and most nausea, vomiting and diarrhea occurred during dose escalation [1][3]. Both weight-loss labels warn about acute kidney injury from volume depletion and say to monitor renal function in patients reporting adverse reactions that could lead to volume depletion; the Wegovy label notes the injury often followed gastrointestinal fluid loss [1][3]. Both labels also say the drug is not recommended in people with severe gastroparesis [1][3].

These drugs lower blood glucose, and the labels say hypoglycemia risk rises with insulin or an insulin secretagogue such as a sulfonylurea; they suggest considering a lower dose of the insulin or sulfonylurea when starting [1][3]. In a Wegovy weight-management trial that included adults with type 2 diabetes, glucose below 54 mg/dL occurred in 6.2% on Wegovy 2.4 mg vs 2.5% on placebo, and the risk was higher with a sulfonylurea [1]. In SURMOUNT-2, hypoglycemia (glucose below 54 mg/dL) was 10.3% with a sulfonylurea vs 2.1% without [3].